Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07011589
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:42.666071+00:00
Published At
2025-06-09T00:00:00+00:00
Record Updated At
2025-06-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Epidermolysis Bullosa (EB)", "Epidermolysis Bullosa Acquisita", "Recessive Dystrophic Epidermolysis Bullosa", "Dystrophic Epidermolysis Bullosa"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-06-09"
protocolSection.identificationModule.nctId
"NCT07011589"
protocolSection.identificationModule.officialTitle
"Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)"
protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Epidermolysis Bullosa (EB) (protocolSection.conditionsModule.conditions)
  • Epidermolysis Bullosa Acquisita (protocolSection.conditionsModule.conditions)
  • Recessive Dystrophic Epidermolysis Bullosa (protocolSection.conditionsModule.conditions)
  • Dystrophic Epidermolysis Bullosa (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.